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Abstract
Purpose—To investigate associations between imaging features and mutational status of clear 
cell renal cell carcinoma (ccRCC).
Materials and methods—This multi-institutional, multi-reader study included 103 patients (77 
men; median age 59 years, range 34–79) with ccRCC examined with CT in 81 patients, MRI in 
19, and both CT and MRI in three; images were downloaded from The Cancer Imaging Archive, 
an NCI-funded project for genome-mapping and analyses. Imaging features [size (mm), margin 
(well-defined or ill-defined), composition (solid or cystic), necrosis (for solid tumors: 0%, 1%–
33%, 34%–66% or >66%), growth pattern (endophytic, <50% exophytic, or ≥50% exophytic), and 
calcification (present, absent, or indeterminate)] were reviewed independently by three readers 
blinded to mutational data. The association of imaging features with mutational status (VHL, 
BAP1, PBRM1, SETD2, KDM5C, and MUC4) was assessed.
Results—Median tumor size was 49 mm (range 14–162 mm), 73 (71%) tumors had well-defined 
margins, 98 (95%) tumors were solid, 95 (92%) showed presence of necrosis, 46 (45%) had ≥50% 
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exophytic component, and 18 (19.8%) had calcification. VHL (n = 52) and PBRM1 (n = 24) were 
the most common mutations. BAP1 mutation was associated with ill-defined margin and presence 
of calcification (p = 0.02 and 0.002, respectively, Pearson’s χ2 test); MUC4 mutation was 
associated with an exophytic growth pattern (p = 0.002, Mann–Whitney U test).
Conclusions—BAP1 mutation was associated with ill-defined tumor margins and presence of 
calcification; MUC4 mutation was associated with exophytic growth. Given the known prognostic 
implications of BAP1 and MUC4 mutations, these results support using radiogenomics to aid in 
prognostication and management.
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Renal cell carcinoma (RCC) is the most common of the renal malignancies that would 
account for an estimated 61,560 new patients and 14,080 deaths in the United States in 2015 
[1]. Clear cell RCC (ccRCC) is the most common histologic subtype of RCC [2] and is a 
genetically heterogeneous and biologically diverse disease [3]. Recent advances in genetics 
have led to the identification of several mutations associated with ccRCC [4–9]. The 
association of a deactivating mutation of von Hippel-Lindau (VHL) tumor suppressor gene, 
located on the short arm of chromosome 3, has been recognized for many years [10–12]. 
Several other mutations, including those involving the BRCA1-associated protein 1 (BAP1), 
polybromo 1 (PBRM1), SET domain containing 2 (SETD2), and lysine (K)-specific 
demethylase 5C (KDM5C) have been identified more recently [4–9]. The identification of 
genetic mutations is clinically relevant because both an advanced stage and poor survival 
have been associated with VHL, PBRM1, BAP1, SETD2, and KDM5C mutations [4, 13–
15]. For example, the BAP1 mutation has been associated with an increased sensitivity to 
radiation therapy and possibly to an increased sensitivity to the inhibitors of mammalian 
target of rapamycin complex 1 (mTORC1 inhibitors) [5, 16]. Therefore, knowledge of the 
genetic make-up of an individual patient’s tumor could help assess the patient’s prognosis, 
and could be considered when planning the treatment [4, 13, 14].
Historically, the role of diagnostic imaging in patients with RCC has been limited to the 
diagnosis and staging of the disease, and to following patients both during and after 
treatment. However, recent advances in cancer genomics have led to an interest in using 
imaging as a noninvasive determinant of mutational status and to complement genomic 
analysis in characterizing disease biology, a ‘sub-field’ known as ‘radiogenomics’ [17]. 
Imaging might then be used as a biomarker that would help prognosticate, aid in treatment 
selection, and predict treatment response [18].
To our knowledge, there has been only one, single-institution report on the association of 
imaging features and mutational status of ccRCC [18]. In order for radiogenomics to be used 
in clinical practice, a larger body of evidence is needed. Therefore, the purpose of this multi-
institutional study was to investigate associations between imaging features and mutational 
status of ccRCC.
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Methods
The cancer genome atlas
The Cancer Genome Atlas (TCGA) is an ongoing project funded by the National Cancer 
Institute (NCI) and the National Human Genome Research Institute (NHGRI) with the 
purpose of creating an atlas of genetic changes related to more than 20 tumor types, 
including ccRCC. After obtaining institutional review board approval at all participating 
institutions, the submitted tissue samples underwent a comprehensive multiplatform 
genomic characterization and analysis. Available pretreatment imaging studies were 
uploaded in DICOM format to the Cancer Imaging Archive (TCIA), an NCI-supported 
archive of anonymized medical images, each connected by a unique identifier to the tissue 
samples from the TCGA, both of which are accessible for public download [19]. The Cancer 
Genome Atlas–Renal Cell Carcinoma (TCGA–RCC) Imaging Research Group was formed 
to study the radiogenomics of ccRCC.
Patient cohort
In this study, we included the first 103 patients from the TCGA data portal (77 men; median 
age 59 years, range 34–79) who had pre-surgical CT scans and/or MRI examinations (81 
had with CT, 19 had MRI, and three had both CT and MRI) available for review. Of the 103 
patients included in our cohort, 78 patients had been included in a separately conducted 
independent study by Karlo et al. [18], the contents of which were not known at the time of 
performing our study.
Image feature set development
The image feature set was developed for the purpose of this study by the TCGA–RCC 
Research Group in consensus. The following features were evaluated for each tumor: size 
(in mm), margin [well-defined (Fig. 1A) or ill-defined (Fig. 1B)], composition [solid (Fig. 
2A) or cystic (Fig. 2B)], necrosis [assessed only for solid tumors: 0%, 1%–33% (Fig. 3A), 
34%–66% (Fig. 3B) or >66% (Fig. 3C)], growth pattern [endophytic (Fig. 4A), <50% 
exophytic (Fig. 4B), or ≥50% exophytic (Fig. 4C)], and calcification [absent, present (Fig. 
5), or indeterminate]. Size was recorded as the maximum tumor dimension in the axial plane 
on nephrographic or excretory phase images. Margin was considered to be well-defined if 
>90% of the entire tumor circumference (including the interface with renal parenchyma, 
sinus and perinephric fat, and collecting system) was ‘pencil-thin’ sharp when viewed on 
either the nephrographic or excretory phase images using a narrow window setting. When 
both nephrographic and excretory phases were available and there was discordance between 
the two, the phase that showed the most well-defined tumor was used. Regarding 
composition, a tumor was considered to be cystic when ≥50% of tumor volume was cystic, 
defined as fluid attenuation values (≤20 Hounsfield Units); a cystic tumor needed to contain 
one or more well-demarcated cystic spaces each of which showing at least 25% their walls 
as smooth. Tumors with <50% cystic component or those without sharply demarcated cystic 
component were considered to be solid. Among solid tumors, the proportion of necrosis 
(defined as hypodense, non-enhancing areas which were not sharply demarcated and lacked 
apparent walls) was assessed on nephrographic or excretory phase. After these image feature 
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definitions were developed in consensus, a training set of 11 cases (not included in the study 
cohort) were scored by the readers.
Image review
Each case was reviewed by three radiologists, randomly assigned from a pool of 13 
academic radiologists from seven teaching institutions, each with fellowship training in 
abdominal imaging (7–16 years of experience). The readers were blinded to the clinical and 
mutational data. The cases were reviewed on a cloud-based virtual machine using the 
ClearCanvas viewer (Version 3.5.0.1 Northwestern University, Chicago, IL) [20–22]. The 
reviewers were able to adjust the image size, window, and level setting. Also, the readers 
could evaluate the images in any available plane (axial, coronal, or sagittal), however, all 
size measurements were obtained in the axial plane. Each ccRCC was independently scored 
by each of the three readers using the predefined feature set. The data were uploaded to a 
central server, and then compiled and analyzed by a statistician.
Mutational status
The presence of mutations in VHL, PBRM1, MUC4, SETD2, BAP1, and KDM5C, the six 
most commonly mutated genes in the TCGA KIRC cohort, was identified for each case 
using the cBioPortal.
Statistical analysis
The inter-observer agreement for tumor size was assessed by computing the intra-class 
correlation coefficient (ICC) [23]; 95% confidence intervals (CI) were computed using the 
technique from Swiger et al. [24]. The inter-observer agreement for the other features was 
assessed using Krippendorff’s alpha [25, 26]; 95% CI for alpha were computed using the 
nonparametric bootstrap, where within each bootstrap iteration, patients were sampled with 
replacement [27]. Krippendorff’s α below 0.667 indicates low inter-observer agreement 
[26].
To analyze the association of each image feature with mutational status, the imaging 
features recorded by the three readers were summarized into a single summary value. For 
tumor size and ordinal features such as the amount of necrosis and growth pattern, the 
median of the values reported by the readers was used as the summary value. For binary 
features such as composition, margin, or the presence of calcification, the most commonly 
selected value among the readers was used as the summary value.
Pearson’s χ2 test was used to test the null hypothesis of no association between individual 
binary features and mutational status. The odds ratio of the association between each binary 
feature and mutational status was also computed, and 95% CI of these odds ratios were 
constructed using parametric bootstrap [28]. Odds ratios greater than one indicate a positive 
association (presence of the image feature is associated with presence of the mutation and 
absence of the image feature is associated with absence of the mutation), whereas those less 
than one indicate a negative association (presence of the image feature is associated with 
absence of the mutation and absence of the image feature is associated with presence of the 
mutation) and those equaling one indicate no association.
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The Mann–Whitney U test was used to analyze the association between individual ordinal 
and quantitative features and mutational status. Concordance probability, namely the 
probability that any randomly chosen patient with a mutation having a higher value of the 
image feature than any randomly chosen patient without the mutation, for each image 
feature and mutation was also computed; the concordance probability equals the Mann–
Whitney U statistic divided by the product of the number of patients with the mutation times 
the number of patients without [29]. 95% CI were constructed using stratified bootstrap [30]. 
Concordance probabilities greater than 0.5 indicate a positive association (greater values of 
the image features are associated with presence of the mutation), whereas those less than 0.5 
indicate a negative association (smaller values of the image features are associated with 
presence of the mutation) and those equaling 0.5 indicate no association. Correction for 
multiple testing was performed through the Benjamini–Hochberg procedure [31]. The 
statistical analyses were performed using R [32].
Results
Imaging features
The median tumor size was 49 mm (range 14–162 mm, interquartile range 34 mm) (Table 
1). Of 103 tumors, 73 (71%) had well-defined margins. The vast majority (98/103, 95%) 
were solid, of which 95 (92%) showed necrosis. Of the 95 tumors with necrosis, 59 had 1%–
33% necrosis, 27 had 34%–66% necrosis, and nine tumors had >66% necrosis. Five (5%) 
tumors were cystic. Most tumors had an exophytic component; 46 (45%) had >50% 
exophytic component, 48 (46%) had <50% exophytic component, and the remaining nine 
(9%) were completely endophytic. Calcification was noted in 18 (19.8%) tumors; 
calcification was not considered evaluable in 12 cases. All the imaging studies evaluated in 
this research project are available online (http://dx.doi.org/10.7937/K9/TCIA.
2014.K6M61GDW).
Inter-observer agreement
Inter-observer agreement for tumor size was very high (ICC = 0.983, 95% CI 0.977, 0.989) 
(Table 1). The inter-observer agreement for margin (α = 0.300; 95% CI 0.145, 0.463) was 
low as the 95% CI for alpha lay strictly below 0.667. For composition (α = 0.558; 95% CI 
0.213, 0.818), necrosis (α = 0.429; 95% CI 0.302, 0.554), calcification (α = 0.722; 95% CI 
0.542, 0.865), and growth pattern (α = 0.640; 95% CI 0.511, 0.763) (Table 1) the alpha was 
low, however, since the CI for alpha included values above 0.667, the degree of agreement 
remained inconclusive.
Mutational status
Of 103 tumors, 67 (65.0%) had at least one mutation; 30 (2.91%) had more than one 
mutation; 23 (22.3%) had two concurrent mutations, 6 (5.83%) had three, and 1 (0.97%) had 
four. VHL (n = 52, 50.5%) and PBRM1 (n = 24, 23.3%) were the most commonly observed 
mutations (Table 2).
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Associations between imaging features and mutational status
Composition was omitted from this part of the analysis since all but five of the cases had 
solid composition leading to numerical instability arising from the low number of tumors 
without solid composition. The p values of the association between individual image 
features and mutational status are given in Table 3. The following associations had p values 
less than 0.05. An ill-defined margin was associated with BAP1 mutation; four of 30 
patients with ill-defined margins and one of 73 patients with well-defined margins had 
BAP1 mutations (p = 0.001). Presence of calcification was associated with presence of a 
BAP1 mutation; four of 18 patients with calcification and one of 73 patients without 
calcification had BAP1 mutations (p < 0.001). An exophytic growth pattern was more often 
associated with MUC4 mutation; seven of 45 patients with more than 50% exophytic growth 
patterns had MUC4 mutations, compared with two of 49 patients with less than 50% 
exophytic growth patterns and none of nine patients with an entirely endophytic pattern (p = 
0.031) (Fig. 6, Table 3). However, none of these associations remained significant after 
adjusting for multiple testing through the Benjamini–Hochberg procedure.
No imaging characteristics were associated with PBRM1, VHL, SETD2, and KDM5C 
mutations.
Discussion
This multi-institutional, multi-reader study found associations between imaging features of 
ccRCC and BAP1 and MUC4 mutations. We found that an ill-defined tumor margin and 
tumor calcification each were associated with the BAP1 mutation. An ill-defined margin has 
been associated with locally infiltrative and overall aggressive ccRCC [5, 33, 34]. The 
BAP1 mutation, found in 15% of ccRCC, is known to be associated with high-grade tumors 
(Fuhrman grade 3 or 4) and poor survival [5, 13]. Therefore, our findings may provide a 
genetic explanation as to why an ill-defined margin may be associated with high-grade 
disease and poor survival in some patients with ccRCC. However, it should be noted that a 
significant number of poorly marginated tumors did not have BAP1 mutation, which 
indicates that further data on the associations between the imaging features and mutational 
status are needed, and also, the ability of individual imaging features to accurately predict 
the mutational status needs to be studied.
To our knowledge, tumor calcifications have not been associated with high-grade disease or 
poor survival; their association with the BAP1 mutation needs to be evaluated further. In 
addition to prognosis, the BAP1 mutation may have therapeutic implications by modestly 
sensitizing ccRCC to the effects of radiation therapy [5, 16]. There are also data that suggest 
that the BAP1 mutation may increase the sensitivity of ccRCC to mTORC1 inhibitors [16]. 
Thus, the identification of an ill-defined tumor margin or tumor calcifications, if ultimately 
proven to be associated with BAP1 mutation, may help in treatment selection in a subset of 
patients with ccRCC.
Kapur et al. reported that the BAP1 mutation is more frequently associated with the presence 
of necrosis on pathology [13]; however, imaging findings of necrosis were not associated 
with the BAP1 mutation in our study. We compared imaging findings, not pathology, to 
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mutation status. It is possible that tumors thought to be necrotic on imaging were not 
necrotic at pathology, and those not thought to be necrotic at imaging may have been 
necrotic at pathology. Also, an association may not have been found due to the small 
number of tumors with the BAP1 mutation.
We found that an exophytic growth pattern of ccRCC was associated with the MUC4 
mutation. Preliminary data obtained from cBio portal suggests that the MUC4 mutation in 
ccRCC is associated with improved survival [4, 15]. An exophytic growth pattern is known 
to be a good prognostic feature of RCC [35]. In a study of 123 renal masses, Venkatesh et al. 
reported that 55% of 49 exophytic tumors were malignant and of the malignant ones, 96% 
were low grade [35]. The better prognosis of exophytic tumors may be related to the fact 
that, in general, they are more easily resected due to their lower R.E.N.A.L. nephrometry 
score [32]. This scoring system takes into account tumor’s radius (“R”), its exophytic (or 
endophytic) location (“E”), nearness (“N”) to the collecting system, whether the tumor is 
anterior (“A”) (or posterior), and the tumor’s location (“L”) in relation to the polar line of 
the kidney [36]. Nevertheless, our study’s finding of an association between an exophytic 
growth pattern and the MUC4 mutation may explain, in part, why this imaging finding is 
associated with improved ccRCC survival [4, 15].
There is a paucity of literature correlating imaging findings of ccRCC with mutational 
status. Karlo et al. [18] found an association between a well-defined tumor margin and the 
VHL mutation and an association between solid ccRCC and mutations of VHL and PBRM1. 
However, these findings were not corroborated in our study despite the fact that many of our 
patients were also evaluated by Karlo et al. The fact that our conclusions differed from 
Karlo et al. [18] could have been due to several factors. First, we defined some imaging 
features differently. For example, we considered a tumor margin to be ‘well-defined’ only 
when more than 90% of the entire tumor circumference was ‘pencil-thin’ sharp. No specific 
definition was described by Karlo et al. Second, we evaluated some imaging features 
differently. For example, we assessed the presence of necrosis only in tumors deemed to be 
solid so as not consider low attenuation cystic regions as necrotic. Karlo et al. assessed for 
the presence of necrosis in every tumor. Third, we did not evaluate the same imaging 
features. For example, Karlo et al. evaluated and reported an association of both nodular 
enhancement and intratumoral vascularity with the VHL mutation, and renal vein invasion 
with KDM5C and BAP1 mutations. Nodular enhancement, intratumoral vascularity, and 
renal vein invasion were not evaluated in our study because our readers could not reach a 
consensus on their definition. Fourth, the data in our study were evaluated by multiple 
readers from multiple institutions. The Karlo et al. study was derived from a single 
institution. The inter-observer agreement was low for most features in our study, whereas 
the study by Karlo et al. reported substantial to excellent interobserver agreement [18]. 
Indeed, readers from a single institution are more likely to interpret images similarly than 
readers from different institutions. However, the results of a multi-institutional study such as 
ours may be easier to generalize. To compensate for inter-observer variability in our study, 
the three readers were asked to interpret the imaging findings independently; the majority 
read for each imaging finding then was used for each case. Overall, the fact that our results 
differed from those of Karlo et al. highlight the difficulties in conducting studies of this 
kind, and prompt the need for a consistent, standard approach to imaging feature analyses.
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This study had several limitations. This was a retrospective study; however, the readers were 
blinded to each patient’s mutational status in order to minimize any bias. The purpose of this 
study was a preliminary assessment of associations between individual image features and 
presence of each mutation; no assessments of the sensitivity and specificity of the image 
features in detecting any of these mutations were performed. Although using these image 
features to detect mutations would be a more clinically relevant question, our objective here 
was to first examine whether the data provided any indication that imaging would have any 
predictive signal. Although none of the associations were significant after adjusting for 
multiple testing, perhaps because of small number of patients with each mutation, the results 
indicate that these image features, in combination with one another, may be able to predict 
mutation status. We plan to validate our findings and calculate the predictive value of each 
imaging finding in a separate, future cohort.
We did not construct multivariate models of mutation status because of relatively small 
number of patients with each mutation. Similarly, the potential effect of the presence of 
multiple simultaneous mutations on the imaging appearance of the tumors or of the multiple 
imaging findings on one mutation both could not be evaluated for the same reason. The 
imaging examinations were performed at multiple academic institutions using different 
scanners and variable technical parameters; the technical details were not available in every 
patient. However, all the patients were examined with protocols that included the requisites 
for renal mass imaging including a maximum section thickness of 5 mm. Although the study 
included both CT scans and MRI examinations, the correlation of findings (such as 
percentage of necrosis and tumor margin) between CT and MRI was not investigated. This 
can be conducted along with in-depth radiology–pathology correlation in a separate future 
study. Finally, although the mutational status of each tumor was derived from surgical 
samples, intratumoral genetic heterogeneity, a known phenomenon in ccRCC [3], may not 
have been fully accounted [37].
Despite these limitations, this multi-institutional, multi-reader study showed an association 
between imaging features and mutational status of ccRCC. Ill-defined margins and tumoral 
calcifications each were associated with the BAP1 mutation, which in clinical studies is 
associated with high-grade tumors and poor survival. An exophytic growth pattern was 
associated with theMUC4 mutation, which is associated with better survival. These results 
indicate that imaging has potential as a non-invasive means of ascertaining mutation status, 
a research question that we hope to investigate in future studies. These findings add to the 
growing data that support the potential for using radiogenomics to predict the genomic 
make-up of ccRCC. Ultimately, when greater evidence accumulates, these data also may 
help predict clinical outcome and response to treatment. However, radiogenomics research 
will need to keep pace with the discovery of new mutations and their therapeutic 
implications. Our study also highlighted the challenges in achieving good interobserver 
agreement from a diverse group of experienced, sub-specialty-trained radiologists. Although 
these data may help develop further the field of radiogenomics and our ability to use 
imaging as a noninvasive biomarker to predict mutational status of ccRCC, the fact that our 
findings differ from the only other analysis of this kind points to the complexity of the 
problems of multi-reader image analysis, genetic mapping, and the heterogeneity of ccRCC.
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Fig. 1. 
Illustration of margin assessment of clear cell RCC (ccRCC): A well-defined margin and B 
ill-defined margin.
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Fig. 2. 
Illustration of composition of ccRCC: A solid and B cystic ccRCC.
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Fig. 3. 
Illustration of presence of necrosis assessed in solid ccRCC: A 1%–33% necrosis; B 34%–
66% necrosis; C >66% necrosis.
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Fig. 4. 
Illustration of growth pattern of ccRCC: A endophytic; B <50% exophytic; C ≥50% 
exophytic.
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Fig. 5. 
Illustration of a ccRCC with presence of calcification.
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Fig. 6. 
Patient-based color map showing the presence of mutations and imaging features in 103 
patients with ccRCC. Margin:  well-defined,  ill-defined; Composition:  solid,  cystic; 
Necrosis:  0%,  1%–33%,  34%–66%,  >66%,  not assessed because of cystic tumor; 
Growth pattern:  endophytic,  <50% exophytic,  ≥50% exophytic; Calcification:  absent, 
 present,  indeterminate.
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Table 1
Imaging features and summary statistics of 103 clear cell renal cell carcinomas (ccRCC)
Imaging feature Levels and summary statistics Inter-observer agreement
Size (cm) Median: 49 mm
First quartile: 35 mm
Third quartile: 70 mm
ICC = 0.983 (0.977, 0.989)
Margin Well-defined: 73 (70.9%)
Ill-defined: 30 (29.1%)
α = 0.300 (0.145, 0.463)
Composition Solid: 98 (95.1%)
Cystic: 5 (4.9%)
α = 0.558 (0.213, 0.818)
Necrosis None: 6 (5.8%)
1%–33%: 57 (55.3%)
34%–67%: 24 (23.3%)
> 67%: 7 (6.8%)
Missing: 9 (8.7%)
α = 0.651 (0.511, 0.769)
Growth pattern Endophytic: 9 (8.7%)
<50% exophytic: 49 (47.6%)
≥50% exophytic: 45 (43.7%)
α = 0.640 (0.511, 0.763)
Calcification Present: 18 (17.5%)
Absent: 73 (70.9%)
Missing: 12 (11.7%)
α = 0.722 (0.542, 0.865)
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Table 2
Presence of mutations in 103 patients with ccRCC
Mutation Number/percentage of patients
VHL 52 (50.5%)
PBRM1 24 (23.3%)
MUC4 9 (8.74%)
SETD2 9 (8.74%)
KDM5C 6 (5.83%)
BAP1 5 (4.85%)
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